A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Hope S. Rugo, Antoinette R. Tan et al.|Breast Cancer Research and Treatment|2017Cited by 18
A phase 2 study of ridaforolimus and dalotuzumab in estrogen receptor positive breast cancerJosé Baselga, Hope S. Rugo, Serafin M. Morales et al.|University of Southern Denmark Research Portal (University of Southern Denmark)|2013Cited by 0